Comparing Integer (NYSE:ITGR) and Nuwellis (NASDAQ:NUWE)

Nuwellis (NASDAQ:NUWE) and Integer (NYSE:ITGR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility & Risk

Nuwellis has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nuwellis and Integer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	0	1	1	1	3.00
Integer	0	1	6	0	2.86

Nuwellis currently has a consensus price target of $17.00, suggesting a potential upside of 1,474.07%. Integer has a consensus price target of $133.86, suggesting a potential upside of 3.77%. Given Nuwellis’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuwellis is more favorable than Integer.

Valuation & Earnings

This table compares Nuwellis and Integer’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.86 million	0.23	-$20.21 million	($290.21)	0.00
Integer	$1.67 billion	2.59	$90.65 million	$2.89	44.64

Integer has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 2.6% of Nuwellis shares are held by insiders. Comparatively, 2.0% of Integer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Nuwellis and Integer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-232.24%	-1,716.60%	-245.90%
Integer	6.31%	11.48%	5.79%

Summary

Integer beats Nuwellis on 11 of the 15 factors compared between the two stocks.

About Nuwellis

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.